How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?

Jin Ying Lu, Yi Yao Chang, Ting Wei Lee, Ming Hsien Wu, Zheng Wei Chen, Yen Ta Huang, Tai Shuan Lai, Leay Kiaw Er, Yen Hung Lin, Vin Cent Wu, Hao Min Cheng, Hsien Li Kao, Charles Jia-Yin Hou, Kwan Dun Wu, Szu Tah Chen, Feng Hsuan Liu

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that, when necessary, using α-adrenergic receptor blocking agents, centrally acting α-adrenergic agonists, and/or non-dihydropyridine calcium channel blockers should be considered to control blood pressure before screening for PA. We recommend temporarily holding β-adrenergic receptor blocking agents, mineralocorticoid receptor antagonists, dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and all diuretics before screening for PA. Further large-scale randomized controlled studies are required to confirm the recommendations.

Original languageEnglish
Pages (from-to)S91-S97
JournalJournal of the Formosan Medical Association
Volume123
DOIs
Publication statusPublished - Mar 2024

Keywords

  • Aldosterone-to-renin ratio
  • Anti-hypertensive medications
  • Centrally acting α-adrenergic agonists
  • Nondihydropyridine calcium channel blockers
  • Primary aldosteronism
  • α-adrenergic receptor blocking agents

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?'. Together they form a unique fingerprint.

Cite this